Results 121 to 130 of about 10,082 (205)

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation. [PDF]

Front Public Health
Qin J, Tang M, Wang X, Shi L, Shao H, Fonseca V, You X, Wang X.   +7 more
europepmc   +1 more source

Glycemic Efficacy and Safety by Using Insulin Degludec and Aspart Guided by a Clinical Decision Support System in Non-Critically Ill Inpatients with Type 2 Diabetes Mellitus. [PDF]

Biosensors (Basel)
Aberer F, Hochfellner DA, Baumann PM, Höll B, Beck P, Pieber TR, Mader JK.   +6 more
europepmc   +1 more source

A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec. [PDF]

Ann Med Surg (Lond)
Abid MA, Abid MH, Afzal MD.
europepmc   +1 more source

Primary Care Recognition of Rabson-Mendenhall Syndrome Despite Absence of Classical Diabetic Symptoms. [PDF]

Am J Case Rep
Al Eisa A, Aldayhani AH.
europepmc   +1 more source

Delayed Hypersensitivity Reaction to Insulin: A Case Report. [PDF]

Cureus
Aharmim M, Lakhal M, Reguig N, El Bourkadi JE.   +3 more
europepmc   +1 more source

Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis. [PDF]

J Diabetes Investig
Wang X, Qin J, Liu Y, Wang X.
europepmc   +1 more source

Glutamic-Aspartic Transaminase

Journal of Biological Chemistry, 1961
openaire   +1 more source

Long-lasting hypoglycemia through insulin degludec during acute kidney injury after diabetic ketoacidosis: A case report. [PDF]

Clin Pediatr Endocrinol
Kawashima S, Suzuki T, Shima H, Suzuki D, Kamimura M, Kikuchi A, Kanno J.   +6 more
europepmc   +1 more source

Efficacy and safety of insulin degludec/aspart in patients with type 2 and type 1 diabetes mellitus: real-world evidence from Indonesia. [PDF]

Front Endocrinol (Lausanne)
Zufry H, Sucipto KW, Ekadamayanti AS, Iqbal Q.   +3 more
europepmc   +1 more source